| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 28.10. | PMGC Holdings Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 08.10. | PMGC Holdings Inc. Announces DBA as NorthStrive Holdings, Inc., Trademark License Agreement, and Website Update | 244 | GlobeNewswire (Europe) | NEWPORT BEACH, Calif., Oct. 08, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (Nasdaq: ELAB) ("NorthStrive Holdings" or the "Company") announces that it has registered a doing-business-as (DBA) name... ► Artikel lesen | |
| 29.09. | PMGC Holdings Inc.: NorthStrive Biosciences Partners with Charles River Laboratories to Advance Its EL-22 and EL-32 Engineered Probiotic Programs | 301 | GlobeNewswire (Europe) | Engagement of a leading global contract research organization strengthens the analytical foundation supporting EL-22 and EL-32 as the programs advance toward an IND-enabling development frameworkBuilds... ► Artikel lesen | |
| 18.09. | PMGC converts Elevai Skincare royalty into payment plan | 2 | Investing.com | ||
| 18.09. | PMGC Holdings Inc. (Nasdaq: ELAB) Secures Five-Year Royalty Stream from Elevai Skincare Sale Under Executed Payment Agreement with Longevity Health Holdings | 3 | GlobeNewswire (USA) | ||
| 18.09. | PMGC Holdings Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| PMGC Aktie jetzt für 0€ handeln | |||||
| 01.09. | PMGC Holdings Inc.: NorthStrive Biosciences Expands AI-Driven Drug Discovery Program with Yuva Biosciences, Advancing Four Novel AI-Discovered Compounds Toward Lead Nomination for Potential Cardiac Disease and Obesity Therapeutic Applications | 528 | GlobeNewswire (Europe) | Building on positive Phase III results from the parties' AI-driven drug discovery program, the six-month Expansion Program will narrow the four validated compounds toward a nominated lead and designated... ► Artikel lesen | |
| 27.08. | PMGC Holdings Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 26.08. | PMGC Holdings Inc.: PMGC Holdings Terminates Previously Announced Acquisition LOI Following Due Diligence Review; Reaffirms Disciplined M&A Strategy and Expands Investment Across Aerospace & Defense Manufacturing Portfolio | 610 | GlobeNewswire (Europe) | NEWPORT BEACH, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (Nasdaq: ELAB) ("PMGC" or the "Company"), a diversified public holding company executing a targeted growth strategy across... ► Artikel lesen | |
| 25.08. | PMGC signs term sheet for space research, manufacturing deal | 1 | Investing.com | ||
| 25.08. | PMGC Holdings Inc.: PMGC Holdings Announces Term Sheet with Orbit2Orbit for NorthStrive Biosciences to Launch a Spaceflight Study of Its Myostatin and Activin A Assets, EL-22 and EL-32, Targeting Microgravity-Induced Muscle Loss | 298 | GlobeNewswire (Europe) | Proposed Mice2Space spaceflight study would evaluate EL-22 and EL-32 in mice in a real-world microgravity environment, targeting one of the most significant physiological challenges of spaceflight... ► Artikel lesen | |
| 21.08. | PMGC Holdings Inc.: NorthStrive Biosciences Announces The Filing of Two U.S. Patent Applications Targeting Microgravity-Induced Muscle Loss During Long-Duration Spaceflight | 763 | GlobeNewswire (Europe) | New Filings Extend EL-22 and EL-32 into Spaceflight-Associated Muscle Atrophy, Broadening NorthStrive's Myostatin and Activin A Intellectual Property Portfolio Across Human Weight-Loss, Space Health... ► Artikel lesen | |
| 19.08. | PMGC Holdings to implement 1-for-10 reverse stock split Thursday | 5 | Investing.com | ||
| 19.08. | PMGC Holdings Inc. Announces Anticipated Reverse Stock Split | 559 | GlobeNewswire (Europe) | NEWPORT BEACH, Calif., Aug. 19, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ: ELAB) ("PMGC" or the "Company") today announced that it will effect a 1-for-10 reverse stock split (the "Split")... ► Artikel lesen | |
| 14.08. | PMGC Holdings Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 14.08. | PMGC Holdings Inc. [NASDAQ: ELAB] Reports Q2 2026 Results and Files Form 10-Q; Total Assets Reach $36.6 Million, Up 184% from Year-End 2025 and 290% Year-over-Year, as Quarterly Revenue Nearly Doubles Sequentially | 613 | GlobeNewswire (Europe) | NEWPORT BEACH, Calif., Aug. 14, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (Nasdaq: ELAB) ("PMGC" or the "Company"), a diversified holding company, has filed its Quarterly Report on Form 10-Q (the... ► Artikel lesen | |
| 29.07. | PMGC Holdings confirms compliance with Nasdaq listing rule | 2 | Investing.com | ||
| 29.07. | PMGC Holdings Inc.: PMGC Holdings Confirms Compliance with Nasdaq's New $5 Million Market Value of Listed Securities Requirement | 248 | GlobeNewswire (Europe) | NEWPORT BEACH, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (Nasdaq: ELAB) ("PMGC" or the "Company"), a diversified public holding company, today confirmed that it is in compliance... ► Artikel lesen | |
| 28.07. | PMGC subsidiary A&B Aerospace signs multi-year manufacturing agreement with PAD Group | - | Seeking Alpha | ||
| 28.07. | PMGC Holdings Inc. Announces Strategic Investment in Precision Aerospace & Defense Group and Long-Term Aerospace and Defense Manufacturing Agreement Through A&B Aerospace Inc. | 387 | GlobeNewswire (Europe) | NEWPORT BEACH, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ: ELAB) (the "Company," "PMGC," "we," or "our"), a diversified holding company executing a precision manufacturing... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 51,84 | +3,64 % | Satte Kursgewinne mit der grünen Transformation! Wie Coca-Cola, Bayer, MustGrow und PepsiCo an die Zukunft denken | Erstellt und veröffentlicht im Auftrag von MustGrow Biologics Corp. Trotz regulatorischer Fortschritte bleibt die Welternährungslage extrem prekär. Laut einem aktuellen Bericht der Welthungerhilfe und... ► Artikel lesen | |
| GILEAD SCIENCES | 149,78 | -1,60 % | BioNTech und Bristol Myers melden 90 Prozent Krankheitskontrolle: Warum neue Therapien Milliardenpotenzial eröffnen - auch Mesoblast im Fokus | ||
| AURORA CANNABIS | 4,580 | +21,36 % | Organigram Global Inc. to Acquire Aurora Cannabis Inc. and Establish a Global Cannabis Leader | • Organigram to acquire Aurora for C$7.80 per Aurora Common Share; Aurora shareholders will have the option to receive such Consideration in cash, Organigram shares or a combination of both, subject... ► Artikel lesen | |
| ABBVIE | 254,60 | -1,36 % | Ihre wichtigsten Termine: Cameco, AbbVie, Chevron, BP, AstraZeneca & General Dynamics mit frischen Updates | © Foto: Andrew Milligan - PA WireGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag Enthaltene Werte:... ► Artikel lesen | |
| ELI LILLY | 1.257,20 | -0,30 % | Klatsche vor Gericht: Lilly 6-mal so viel wert wie Novo: Wird der Abstand jetzt noch größer? | © Foto: Sascha Lotz/dpaNovo Nordisk scheitert vor Gericht mit dem Versuch, Lillys Abnehm-Werbung zu stoppen. An der Börse ist Lilly längst sechsmal so viel wert. Ist Novo jetzt ein Schnäppchen oder... ► Artikel lesen | |
| CANOPY GROWTH | 0,639 | +5,00 % | Cannabissektor in Aufruhr: Drama um Tilray-Zahlen: Anleger zittern nun vor Canopy, Aurora Cannabis & Co. | © Foto: adobe.stock.comAbseits haussierender Ölpreise und wankender Aktienmärkte findet das Siechtum im Cannabis-Sektor seine Fortsetzung. Der Quartalsbericht von Tilray sollte neue Hoffnung bringen... ► Artikel lesen | |
| ASTRAZENECA | 163,60 | -1,89 % | RBC stuft ASTRAZENECA auf 'Outperform' | NEW YORK (dpa-AFX Analyser) - Die kanadische Bank RBC hat Astrazeneca nach einer Investorenveranstaltung im Rahmen des Onkologiekongresses ESMO mit einem Kursziel von 14500 Pence auf "Outperform" belassen.... ► Artikel lesen | |
| TILRAY BRANDS | 2,385 | +4,84 % | Tilray Brands targets $20M in cost savings after craft brewery closures | ||
| BRISTOL-MYERS SQUIBB | 55,17 | -2,01 % | Dividendenbekanntmachungen (02.11.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABM INDUSTRIES INC US0009571003 0,29 USD EUR ACUITY INC US00508Y1029 0,2 USD EUR AMERISERV FINANCIAL INC US03074A1025 0,03... ► Artikel lesen | |
| TEVA PHARMACEUTICAL INDUSTRIES | 41,905 | +0,04 % | Teva Pharmaceutical Industries Limited Q3 Income Declines | PETAH TIKVA (dpa-AFX) - Teva Pharmaceutical Industries Limited (TEVA) announced a profit for third quarter that Drops, from last yearThe company's bottom line came in at $233 million, or $0.20... ► Artikel lesen | |
| ABBOTT LABORATORIES | 97,88 | -0,65 % | US-Börse: 46 Aktien schufen $45,5 Billionen | © Foto: Lee Woodgate - Ikon ImagesEine Studie des US-Finanzwissenschaftlers Hendrik Bessembinder kommt zu dem Schluss, dass die Hälfte des in den letzten 100 Jahren an der US-Börse erwirtschafteten... ► Artikel lesen | |
| TAAT GLOBAL ALTERNATIVES | 0,136 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -2- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameCA83013Q8719 CORE... ► Artikel lesen | |
| DERMAPHARM | 38,750 | -0,90 % | JEFFERIES stuft Dermapharm auf 'Hold' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Dermapharm nach einem Treffen mit dem Finanzchef Christof Dreibholz mit einem Kursziel von 44 Euro auf "Hold" belassen.... ► Artikel lesen | |
| MPH HEALTH CARE | 28,800 | -0,69 % | Original-Research: MPH Health Care AG (von First Berlin Equity Research GmbH): Kaufen | Original-Research: MPH Health Care AG - from First Berlin Equity Research GmbH
21.09.2026 / 13:15 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer... ► Artikel lesen | |
| ARZNEIWERK AG VIDA | 0,145 | 0,00 % | PTA-AFR: Arzneiwerk AG VIDA: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG | DJ PTA-AFR: Arzneiwerk AG VIDA: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG
Vorabbekanntmachung Finanzberichte gemäß ---- 114-117 WpHG
Arzneiwerk... ► Artikel lesen |